Your browser doesn't support javascript.
loading
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.
Mazor, Tali; Chesnelong, Charles; Pankov, Aleksandr; Jalbert, Llewellyn E; Hong, Chibo; Hayes, Josie; Smirnov, Ivan V; Marshall, Roxanne; Souza, Camila F; Shen, Yaoqing; Viswanath, Pavithra; Noushmehr, Houtan; Ronen, Sabrina M; Jones, Steven J M; Marra, Marco A; Cairncross, J Gregory; Perry, Arie; Nelson, Sarah J; Chang, Susan M; Bollen, Andrew W; Molinaro, Annette M; Bengtsson, Henrik; Olshen, Adam B; Weiss, Samuel; Phillips, Joanna J; Luchman, H Artee; Costello, Joseph F.
Afiliação
  • Mazor T; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Chesnelong C; Hotchkiss Brain Institute, Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Pankov A; Clark H. Smith Brain Tumor Center, Arnie Charbonneau Cancer Institute, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Jalbert LE; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Hong C; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158.
  • Hayes J; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Smirnov IV; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Marshall R; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Souza CF; Department of Pathology, University of California, San Francisco, CA 94158.
  • Shen Y; Department of Neurosurgery, Henry Ford Health System, Detroit, MI 48202.
  • Viswanath P; Department of Genetics, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil.
  • Noushmehr H; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
  • Ronen SM; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158.
  • Jones SJM; Department of Neurosurgery, Henry Ford Health System, Detroit, MI 48202.
  • Marra MA; Department of Genetics, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil.
  • Cairncross JG; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158.
  • Perry A; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
  • Nelson SJ; Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4S6, Canada.
  • Chang SM; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
  • Bollen AW; Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4S6, Canada.
  • Molinaro AM; Clark H. Smith Brain Tumor Center, Arnie Charbonneau Cancer Institute, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Bengtsson H; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Olshen AB; Department of Pathology, University of California, San Francisco, CA 94158.
  • Weiss S; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158.
  • Phillips JJ; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158.
  • Luchman HA; Department of Neurological Surgery, University of California, San Francisco, CA 94158.
  • Costello JF; Department of Pathology, University of California, San Francisco, CA 94158.
Proc Natl Acad Sci U S A ; 114(40): 10743-10748, 2017 10 03.
Article em En | MEDLINE | ID: mdl-28916733
ABSTRACT
IDH1 mutation is the earliest genetic alteration in low-grade gliomas (LGGs), but its role in tumor recurrence is unclear. Mutant IDH1 drives overproduction of the oncometabolite d-2-hydroxyglutarate (2HG) and a CpG island (CGI) hypermethylation phenotype (G-CIMP). To investigate the role of mutant IDH1 at recurrence, we performed a longitudinal analysis of 50 IDH1 mutant LGGs. We discovered six cases with copy number alterations (CNAs) at the IDH1 locus at recurrence. Deletion or amplification of IDH1 was followed by clonal expansion and recurrence at a higher grade. Successful cultures derived from IDH1 mutant, but not IDH1 wild type, gliomas systematically deleted IDH1 in vitro and in vivo, further suggestive of selection against the heterozygous mutant state as tumors progress. Tumors and cultures with IDH1 CNA had decreased 2HG, maintenance of G-CIMP, and DNA methylation reprogramming outside CGI. Thus, while IDH1 mutation initiates gliomagenesis, in some patients mutant IDH1 and 2HG are not required for later clonal expansions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amplificação de Genes / Deleção de Sequência / Epigenômica / Glioma / Isocitrato Desidrogenase / Mutação / Recidiva Local de Neoplasia Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amplificação de Genes / Deleção de Sequência / Epigenômica / Glioma / Isocitrato Desidrogenase / Mutação / Recidiva Local de Neoplasia Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2017 Tipo de documento: Article